Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Join us to learn about plans for the RPGRIP1 Gene Therapy Program in 2022. Several key milestones for the RPGRIP1 Program were achieved in 2021. Odylia Therapeutics will present a summary of these benchmarks and what it means for the program. We'll also discuss the plans...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting details: Tuesday,...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....